SOX2 and cancer: BTK silencing significantly decreased the expression of the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) and, in consequence, reduced cancer cell viability via the SRY-box transcription factor 2 (Sox-2) and BCL-XL genes and increased susceptibility to cisplatin [56].